Imaging of Iron

International Review of Neurobiology

Volumn 110, Issue , 2013, Pages 195-239

  Dusek, Petr ^a,b   Dezortova, Monika ^c   Wuerfel, Jens ^b,d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Chelating agents; Iron; MRI; NBIA; Neurodegeneration; Relaxometry; SWI

Indexed keywords

FERRITIN; HEMOSIDERIN; IRON; METAL ION; MYELIN; WATER;

ACCURACY; ARTICLE; BIOACCUMULATION; BRAIN MAPPING; CELLULAR DISTRIBUTION; FIELD DEPENDENT RELAXOMETRY; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; IRON METABOLISM; IRON TRANSPORT; MAGNETIC FIELD CORRELATION IMAGING; MAGNETIC RESONANCE RELAXOMETRY; MOLECULAR DYNAMICS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN CONTENT; QUANTITATIVE ANALYSIS; QUANTITATIVE SUSCEPTIBILITY IMAGING; SENSITIVITY ANALYSIS; SIGNAL DETECTION; SUSCEPTIBILITY WEIGHTED IMAGING; VASCULAR DISEASE;

CHELATING AGENTS; IRON; MRI; NBIA; NEURODEGENERATION; RELAXOMETRY; SWI;

BRAIN; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES;

EID: 84887232075     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-410502-7.00010-7     Document Type: Chapter

References (209)

1. Adisetiyo V., Jensen J.H., Ramani A., Tabesh A., Di Martino A., Fieremans E., et al. In vivo assessment of age-related brain iron differences by magnetic field correlation imaging. Journal of Magnetic Resonance Imaging 2012, 36(2):322-331.
2. Aquino D., Bizzi A., Grisoli M., Garavaglia B., Bruzzone M.G., Nardocci N., et al. Age-related iron deposition in the basal ganglia: Quantitative analysis in healthy subjects. Radiology 2009, 252(1):165-172.
3. Arabia G., Morelli M., Paglionico S., Novellino F., Salsone M., Giofre L., et al. An magnetic resonance imaging T2*-weighted sequence at short echo time to detect putaminal hypointensity in Parkinsonisms. Movement Disorders 2010, 25(16):2728-2734.
4. Attieh Z.K., Mukhopadhyay C.K., Seshadri V., Tripoulas N.A., Fox P.L. Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism. Journal of Biological Chemistry 1999, 274(2):1116-1123.
5. Bagnato F., Hametner S., Yao B., van Gelderen P., Merkle H., Cantor F.K., et al. Tracking iron in multiple sclerosis: A combined imaging and histopathological study at 7 Tesla. Brain 2011, 134(Pt 12):3599-3612.
6. Bakshi R., Dmochowski J., Shaikh Z.A., Jacobs L. Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. Journal of Neurological Sciences 2001, 185(1):19-26.
7. Bartzokis G., Aravagiri M., Oldendorf W.H., Mintz J., Marder S.R. Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores. Magnetic Resonance in Medicine 1993, 29(4):459-464.
8. Bartzokis G., Beckson M., Hance D.B., Marx P., Foster J.A., Marder S.R. MR evaluation of age-related increase of brain iron in young adult and older normal males. Magnetic Resonance Imaging 1997, 15(1):29-35.
9. Bartzokis G., Cummings J.L., Markham C.H., Marmarelis P.Z., Treciokas L.J., Tishler T.A., et al. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magnetic Resonance Imaging 1999, 17(2):213-222.
10. Bartzokis G., Cummings J., Perlman S., Hance D.B., Mintz J. Increased basal ganglia iron levels in Huntington disease. Archives of Neurology 1999, 56(5):569-574.
11. Bartzokis G., Sultzer D., Mintz J., Holt L.E., Marx P., Phelan C.K., et al. In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI. Biological Psychiatry 1994, 35(7):480-487.
12. Bartzokis G., Tishler T.A. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. Cell and Molecular Biology (Noisy-le-grand) 2000, 46(4):821-833.
13. Bartzokis G., Tishler T.A., Lu P.H., Villablanca P., Altshuler L.L., Carter M., et al. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiology of Aging 2007, 28(3):414-423.
14. Bender B., Klose U. The in vivo influence of white matter fiber orientation towards B(0) on T2* in the human brain. NMR in Biomedicine 2010, 23(9):1071-1076.
15. Berg D. In vivo detection of iron and neuromelanin by transcranial sonography-A new approach for early detection of substantia nigra damage. Journal of Neural Transmission 2006, 113(6):775-780.
16. Bilgic B., Pfefferbaum A., Rohlfing T., Sullivan E.V., Adalsteinsson E. MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. NeuroImage 2012, 59(3):2625-2635.
17. Boddaert N., Le Quan Sang K.H., Rotig A., Leroy-Willig A., Gallet S., Brunelle F., et al. Selective iron chelation in Friedreich ataxia: Biologic and clinical implications. Blood 2007, 110(1):401-408.
18. Boelmans K., Holst B., Hackius M., Finsterbusch J., Gerloff C., Fiehler J., et al. Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy. Movement Disorders 2012, 27(3):421-427.
19. Boltshauser E., Lang W., Janzer R., Briner J., Spiess H., Kleihues P., et al. Computed tomography in Hallervorden-Spatz disease. Neuropediatrics 1987, 18(2):81-83.
20. Brittenham G.M., Badman D.G., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Workshop Noninvasive measurement of iron: Report of an NIDDK workshop. Blood 2003, 101(1):15-19.
21. Brooks D.J., Luthert P., Gadian D., Marsden C.D. Does signal-attenuation on high-field T2-weighted MRI of the brain reflect regional cerebral iron deposition? Observations on the relationship between regional cerebral water proton T2 values and iron levels. Journal of Neurology, Neurosurgery, and Psychiatry 1989, 52(1):108-111.
22. Brooks R.A., Vymazal J., Bulte J.W., Baumgarner C.D., Tran V. Comparison of T2 relaxation in blood, brain, and ferritin. Journal of Magnetic Resonance Imaging 1995, 5(4):446-450.
23. Brooks R.A., Vymazal J., Goldfarb R.B., Bulte J.W., Aisen P. Relaxometry and magnetometry of ferritin. Magnetic Resonance in Medicine 1998, 40(2):227-235.
24. Bruehlmeier M., Leenders K.L., Vontobel P., Calonder C., Antonini A., Weindl A. Increased cerebral iron uptake in Wilson's disease: A 52Fe-citrate PET study. Journal of Nuclear Medicine 2000, 41(5):781-787.
25. Bulte J.W., Miller G.F., Vymazal J., Brooks R.A., Frank J.A. Hepatic hemosiderosis in non-human primates: Quantification of liver iron using different field strengths. Magnetic Resonance in Medicine 1997, 37(4):530-536.
26. Bulte J.W., Vymazal J., Brooks R.A., Pierpaoli C., Frank J.A. Frequency dependence of MR relaxation times II. Iron oxides. Journal of Magnetic Resonance Imaging 1993, 3(4):641-648.
27. Burgetova A., Seidl Z., Krasensky J., Horakova D., Vaneckova M. Multiple sclerosis and the accumulation of iron in the Basal Ganglia: Quantitative assessment of brain iron using MRI t(2) relaxometry. European Neurology 2010, 63(3):136-143.
28. Casanova M.F., Araque J.M. Mineralization of the basal ganglia: Implications for neuropsychiatry, pathology and neuroimaging. Psychiatry Research 2003, 121(1):59-87.
29. Chen J.C., Hardy P.A., Clauberg M., Joshi J.G., Parravano J., Deck J.H., et al. T2 values in the human brain: Comparison with quantitative assays of iron and ferritin. Radiology 1989, 173(2):521-526.
30. Chen J.C., Hardy P.A., Kucharczyk W., Clauberg M., Joshi J.G., Vourlas A., et al. MR of human postmortem brain tissue: Correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. American Journal of Neuroradiology 1993, 14(2):275-281.
31. Chen Z., Johnston L.A., Kwon D.H., Oh S.H., Cho Z.H., Egan G.F. An optimised framework for reconstructing and processing MR phase images. NeuroImage 2010, 49(2):1289-1300.
32. Cheng Y.C., Neelavalli J., Haacke E.M. Limitations of calculating field distributions and magnetic susceptibilities in MRI using a Fourier based method. Physics in Medicine and Biology 2009, 54(5):1169-1189.
33. Cho Z.H., Oh S.H., Kim J.M., Park S.Y., Kwon D.H., Jeong H.J., et al. Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging. Movement Disorders 2011, 26(4):713-718.
34. Connor J.R., Menzies S.L. Altered cellular distribution of iron in the central nervous system of myelin deficient rats. Neuroscience 1990, 34(1):265-271.
35. Connor J.R., Menzies S.L., St Martin S.M., Mufson E.J. Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. Journal of Neuroscience Research 1990, 27(4):595-611.
36. Connor J.R., Ponnuru P., Wang X.S., Patton S.M., Allen R.P., Earley C.J. Profile of altered brain iron acquisition in restless legs syndrome. Brain 2011, 134(Pt 4):959-968.
37. Connor J.R., Snyder B.S., Beard J.L., Fine R.E., Mufson E.J. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. Journal of Neuroscience Research 1992, 31(2):327-335.
38. Curnes J.T., Burger P.C., Djang W.T., Boyko O.B. MR imaging of compact white matter pathways. American Journal of Neuroradiology 1988, 9(6):1061-1068.
39. Daugherty A., Raz N. Age-related differences in iron content of subcortical nuclei observed in vivo: A meta-analysis. NeuroImage 2013, 70:113-121.
40. De Reuck J., Auger F., Cordonnier C., Deramecourt V., Durieux N., Pasquier F., et al. Comparison of 7.0-TT(2)*-magnetic resonance imaging of cerebral bleeds in post-mortem brain sections of Alzheimer patients with their neuropathological correlates. Cerebrovascular Diseases 2011, 31(5):511-517.
41. de Rochefort L., Brown R., Prince M.R., Wang Y. Quantitative MR susceptibility mapping using piece-wise constant regularized inversion of the magnetic field. Magnetic Resonance in Medicine 2008, 60(4):1003-1009.
42. de Rochefort L., Liu T., Kressler B., Liu J., Spincemaille P., Lebon V., et al. Quantitative susceptibility map reconstruction from MR phase data using bayesian regularization: Validation and application to brain imaging. Magnetic Resonance in Medicine 2010, 63(1):194-206.
43. Deistung A., Schafer A., Schweser F., Biedermann U., Turner R., Reichenbach J.R. Toward in vivo histology: A comparison of quantitative susceptibility mapping (QSM) with magnitude-, phase-, and R2*-imaging at ultra-high magnetic field strength. NeuroImage 2013, 65:299-314.
44. Denk C., Hernandez Torres E., MacKay A., Rauscher A. The influence of white matter fibre orientation on MR signal phase and decay. NMR in Biomedicine 2011, 24(3):246-252.
45. Dezortova M., Herynek V., Krssak M., Kronerwetter C., Trattnig S., Hajek M. Two forms of iron as an intrinsic contrast agent in the basal ganglia of PKAN patients. Contrast Media & Molecular Imaging 2012, 7(6):509-515.
46. Dietrich R.B., Bradley W.G. Iron accumulation in the basal ganglia following severe ischemic-anoxic insults in children. Radiology 1988, 168(1):203-206.
47. Doyle F.H., Pennock J.M., Banks L.M., McDonnell M.J., Bydder G.M., Steiner R.E., et al. Nuclear magnetic resonance imaging of the liver: Initial experience. American Journal of Roentgenology 1982, 138(2):193-200.
48. Drayer B., Burger P., Darwin R., Riederer S., Herfkens R., Johnson G.A. MRI of brain iron. American Journal of Roentgenology 1986, 147(1):103-110.
49. Du G., Lewis M.M., Styner M., Shaffer M.L., Sen S., Yang Q.X., et al. Combined R2 and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Movement Disorders 2011, 26(9):1627-1632.
50. Dumas E.M., Versluis M.J., van den Bogaard S.J., van Osch M.J., Hart E.P., van Roon-Mom W.M., et al. Elevated brain iron is independent from atrophy in Huntington's Disease. NeuroImage 2012, 61(3):558-564.
51. Dusek P., Jankovic J., Le W. Iron dysregulation in movement disorders. Neurobiology of Disease 2012, 46(1):1-18.
52. Dusek P., Schneider S.A. Neurodegeneration with brain iron accumulation. Current Opinion in Neurology 2012, 25(4):499-506.
53. Duyn J. MR susceptibility imaging. Journal of Magnetic Resonance 2013, 229:198-207.
54. Duyn J.H., van Gelderen P., Li T.Q., de Zwart J.A., Koretsky A.P., Fukunaga M. High-field MRI of brain cortical substructure based on signal phase. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(28):11796-11801.
55. Engelhardt R., Langkowski J.H., Fischer R., Nielsen P., Kooijman H., Heinrich H.C., et al. Liver iron quantification: Studies in aqueous iron solutions, iron overloaded rats, and patients with hereditary hemochromatosis. Magnetic Resonance Imaging 1994, 12(7):999-1007.
56. Fazekas F., Kleinert R., Roob G., Kleinert G., Kapeller P., Schmidt R., et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: Evidence of microangiopathy-related microbleeds. American Journal of Neuroradiology 1999, 20(4):637-642.
57. Fishman J.B., Rubin J.B., Handrahan J.V., Connor J.R., Fine R.E. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. Journal of Neuroscience Research 1987, 18(2):299-304.
58. Fleming R.E., Ponka P. Iron overload in human disease. New England Journal of Medicine 2012, 366(4):348-359.
59. Fukunaga M., Li T.Q., van Gelderen P., de Zwart J.A., Shmueli K., Yao B., et al. Layer-specific variation of iron content in cerebral cortex as a source of MRI contrast. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(8):3834-3839.
60. Ge Y., Jensen J.H., Lu H., Helpern J.A., Miles L., Inglese M., et al. Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. American Journal of Neuroradiology 2007, 28(9):1639-1644.
61. Gebril O.H., Simpson J.E., Kirby J., Brayne C., Ince P.G. Brain iron dysregulation and the risk of ageing white matter lesions. Neuromolecular Medicine 2011, 13(4):289-299.
62. Gelman N., Ewing J.R., Gorell J.M., Spickler E.M., Solomon E.G. Interregional variation of longitudinal relaxation rates in human brain at 3.0T: Relation to estimated iron and water contents. Magnetic Resonance in Medicine 2001, 45(1):71-79.
63. Gelman N., Gorell J.M., Barker P.B., Savage R.M., Spickler E.M., Windham J.P., et al. MR imaging of human brain at 3.0T: Preliminary report on transverse relaxation rates and relation to estimated iron content. Radiology 1999, 210(3):759-767.
64. Gerber M.R., Connor J.R. Do oligodendrocytes mediate iron regulation in the human brain?. Annals of Neurology 1989, 26(1):95-98.
65. Gorell J.M., Ordidge R.J., Brown G.G., Deniau J.C., Buderer N.M., Helpern J.A. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995, 45(6):1138-1143.
66. Gossuin Y., Burtea C., Monseux A., Toubeau G., Roch A., Muller R.N., et al. Ferritin-induced relaxation in tissues: An in vitro study. Journal of Magnetic Resonance Imaging 2004, 20(4):690-696.
67. Gossuin Y., Gillis P., Muller R.N., Hocq A. Relaxation by clustered ferritin: A model for ferritin-induced relaxation in vivo. NMR in Biomedicine 2007, 20(8):749-756.
68. Gossuin Y., Muller R.N., Gillis P. Relaxation induced by ferritin: A better understanding for an improved MRI iron quantification. NMR in Biomedicine 2004, 17(7):427-432.
69. Gossuin Y., Roch A., Muller R.N., Gillis P. Relaxation induced by ferritin and ferritin-like magnetic particles: The role of proton exchange. Magnetic Resonance in Medicine 2000, 43(2):237-243.
70. Graham J.M., Paley M.N., Grunewald R.A., Hoggard N., Griffiths P.D. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 2000, 123(Pt 12):2423-2431.
71. Gupta R.K., Rao S.B., Jain R., Pal L., Kumar R., Venkatesh S.K., et al. Differentiation of calcification from chronic hemorrhage with corrected gradient echo phase imaging. Journal of Computer Assisted Tomography 2001, 25(5):698-704.
72. Gupta D., Saini J., Kesavadas C., Sarma P.S., Kishore A. Utility of susceptibility-weighted MRI in differentiating Parkinson's disease and atypical parkinsonism. Neuroradiology 2010, 52(12):1087-1094.
73. Haacke E.M., Ayaz M., Khan A., Manova E.S., Krishnamurthy B., Gollapalli L., et al. Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs. abnormal iron content in the brain. Journal of Magnetic Resonance Imaging 2007, 26(2):256-264.
74. Haacke E.M., Cheng N.Y., House M.J., Liu Q., Neelavalli J., Ogg R.J., et al. Imaging iron stores in the brain using magnetic resonance imaging. Magnetic Resonance Imaging 2005, 23(1):1-25.
75. Haacke E.M., Miao Y., Liu M., Habib C.A., Katkuri Y., Liu T., et al. Correlation of putative iron content as represented by changes in R2 and phase with age in deep gray matter of healthy adults. Journal of Magnetic Resonance Imaging 2010, 32(3):561-576.
76. Hallgren B., Sourander P. The effect of age on the non-haemin iron in the human brain. Journal of Neurochemistry 1958, 3(1):41-51.
77. Hammond K.E., Lupo J.M., Xu D., Metcalf M., Kelley D.A., Pelletier D., et al. Development of a robust method for generating 7.0T multichannel phase images of the brain with application to normal volunteers and patients with neurological diseases. NeuroImage 2008, 39(4):1682-1692.
78. Han Y.H., Lee J.H., Kang B.M., Mun C.W., Baik S.K., Shin Y.I., et al. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy. Journal of Neurological Sciences 2013, 325(1-2):29-35.
79. Haque T.L., Miki Y., Kanagaki M., Takahashi T., Yamamoto A., Konishi J., et al. MR contrast of ferritin and hemosiderin in the brain: Comparison among gradient-echo, conventional spin-echo and fast spin-echo sequences. European Journal of Radiology 2003, 48(3):230-236.
80. Harder S.L., Hopp K.M., Ward H., Neglio H., Gitlin J., Kido D. Mineralization of the deep gray matter with age: A retrospective review with susceptibility-weighted MR imaging. American Journal of Neuroradiology 2008, 29(1):176-183.
81. Hasan K.M., Walimuni I.S., Kramer L.A., Narayana P.A. Human brain iron mapping using atlas-based T2 relaxometry. Magnetic Resonance in Medicine 2012, 67(3):731-739.
82. He X., Yablonskiy D.A. Biophysical mechanisms of phase contrast in gradient echo MRI. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(32):13558-13563.
83. Herynek V., Babis M., Trunecka P., Filip K., Vymazal J., Dezortova M., et al. Chronic liver disease: Relaxometry in the brain after liver transplantation. Magnetic Resonance Materials in Physics Biology and Medicine 2001, 12(1):10-15.
84. Herynek V., Wagnerova D., Hejlova I., Dezortova M., Hajek M. Changes in the brain during long-term follow-up after liver transplantation. Journal of Magnetic Resonance Imaging 2012, 35(6):1332-1337.
85. Hikita T., Abe K., Sakoda S., Tanaka H., Murase K., Fujita N. Determination of transverse relaxation rate for estimating iron deposits in central nervous system. Neuroscience Research 2005, 51(1):67-71.
86. Hocq A., Brouette N., Saussez S., Luhmer M., Gillis P., Gossuin Y. Variable-field relaxometry of iron-containing human tissues: A preliminary study. Contrast Media & Molecular Imaging 2009, 4(4):157-164.
87. Hopp K., Popescu B.F., McCrea R.P., Harder S.L., Robinson C.A., Haacke M.E., et al. Brain iron detected by SWI high pass filtered phase calibrated with synchrotron X-ray fluorescence. Journal of Magnetic Resonance Imaging 2010, 31(6):1346-1354.
88. House M.J., St Pierre T.G., Kowdley K.V., Montine T., Connor J., Beard J., et al. Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from Alzheimer's disease patients. Magnetic Resonance in Medicine 2007, 57(1):172-180.
89. Jendelova P., Herynek V., DeCroos J., Glogarova K., Andersson B., Hajek M., et al. Imaging the fate of implanted bone marrow stromal cells labeled with superparamagnetic nanoparticles. Magnetic Resonance in Medicine 2003, 50(4):767-776.
90. Jensen J.H., Chandra R., Ramani A., Lu H., Johnson G., Lee S.P., et al. Magnetic field correlation imaging. Magnetic Resonance in Medicine 2006, 55(6):1350-1361.
91. Jensen J.H., Szulc K., Hu C., Ramani A., Lu H., Xuan L., et al. Magnetic field correlation as a measure of iron-generated magnetic field inhomogeneities in the brain. Magnetic Resonance in Medicine 2009, 61(2):481-485.
92. Jensen J.H., Tang H., Tosti C.L., Swaminathan S.V., Nunez A., Hultman K., et al. Separate MRI quantification of dispersed (ferritin-like) and aggregated (hemosiderin-like) storage iron. Magnetic Resonance in Medicine 2010, 63(5):1201-1209.
93. Jin L., Wang J., Zhao L., Jin H., Fei G., Zhang Y., et al. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 2011, 134(Pt 1):50-58.
94. Jirak D., Kriz J., Herynek V., Andersson B., Girman P., Burian M., et al. MRI of transplanted pancreatic islets. Magnetic Resonance in Medicine 2004, 52(6):1228-1233.
95. Johansson A.C., Appelqvist H., Nilsson C., Kagedal K., Roberg K., Ollinger K. Regulation of apoptosis-associated lysosomal membrane permeabilization. Apoptosis: An International Journal on Programmed Cell Death 2010, 15(5):527-540.
96. Kamman R.L., Go K.G., Brouwer W., Berendsen H.J. Nuclear magnetic resonance relaxation in experimental brain edema: Effects of water concentration, protein concentration, and temperature. Magnetic Resonance in Medicine 1988, 6(3):265-274.
97. Khalil M., Enzinger C., Langkammer C., Tscherner M., Wallner-Blazek M., Jehna M., et al. Quantitative assessment of brain iron by R(2) relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Multiple Sclerosis 2009, 15(9):1048-1054.
98. Khalil M., Langkammer C., Ropele S., Petrovic K., Wallner-Blazek M., Loitfelder M., et al. Determinants of brain iron in multiple sclerosis: A quantitative 3T MRI study. Neurology 2011, 77(18):1691-1697.
99. Koenig S.H., Brown R.D., Gibson J.F., Ward R.J., Peters T.J. Relaxometry of ferritin solutions and the influence of the Fe3+ core ions. Magnetic Resonance in Medicine 1986, 3(5):755-767.
100. Kostic V.S., Svetel M., Mijajlovic M., Pavlovic A., Jecmenica-Lukic M., Kozic D. Transcranial sonography in pantothenate kinase-associated neurodegeneration. Journal of Neurology 2012, 259(5):959-964.
101. Kruer M.C., Boddaert N., Schneider S.A., Houlden H., Bhatia K.P., Gregory A., et al. Neuroimaging features of neurodegeneration with brain iron accumulation. American Journal of Neuroradiology 2012, 33(3):407-414.
102. Kwan J.Y., Jeong S.Y., Van Gelderen P., Deng H.X., Quezado M.M., Danielian L.E., et al. Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: Correlating 7 tesla MRI and pathology. PLoS One 2012, 7(4):e35241.
103. Langkammer C., Krebs N., Goessler W., Scheurer E., Ebner F., Yen K., et al. Quantitative MR imaging of brain iron: A postmortem validation study. Radiology 2010, 257(2):455-462.
104. Langkammer C., Krebs N., Goessler W., Scheurer E., Yen K., Fazekas F., et al. Susceptibility induced gray-white matter MRI contrast in the human brain. NeuroImage 2012, 59(2):1413-1419.
105. Langkammer C., Liu T., Khalil M., Enzinger C., Jehna M., Fuchs S., et al. Quantitative susceptibility mapping in multiple sclerosis. Radiology 2013, 267(2):551-559.
106. Langkammer C., Schweser F., Krebs N., Deistung A., Goessler W., Scheurer E., et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. NeuroImage 2012, 62(3):1593-1599.
107. Lee J., Shmueli K., Kang B.T., Yao B., Fukunaga M., van Gelderen P., et al. The contribution of myelin to magnetic susceptibility-weighted contrasts in high-field MRI of the brain. NeuroImage 2012, 59(4):3967-3975.
108. Lee J., van Gelderen P., Kuo L.W., Merkle H., Silva A.C., Duyn J.H. T2*-based fiber orientation mapping. NeuroImage 2011, 57(1):225-234.
109. Levi S., Rovida E. The role of iron in mitochondrial function. Biochimica et Biophysica Acta 2009, 1790(7):629-636.
110. Li X., Jankovic J., Le W. Iron chelation and neuroprotection in neurodegenerative diseases. Journal of Neural Transmission 2011, 118(3):473-477.
111. Li W., Wu B., Avram A.V., Liu C. Magnetic susceptibility anisotropy of human brain in vivo and its molecular underpinnings. NeuroImage 2012, 59(3):2088-2097.
112. Li T.Q., Yao B., van Gelderen P., Merkle H., Dodd S., Talagala L., et al. Characterization of T(2) heterogeneity in human brain white matter. Magnetic Resonance in Medicine 2009, 62(6):1652-1657.
113. Liem M.K., Lesnik Oberstein S.A., Versluis M.J., Maat-Schieman M.L., Haan J., Webb A.G., et al. 7T MRI reveals diffuse iron deposition in putamen and caudate nucleus in CADASIL. Journal of Neurology, Neurosurgery, and Psychiatry 2012, 83(12):1180-1185.
114. Liman J., Wellmer A., Rostasy K., Bahr M., Kermer P. Transcranial ultrasound in neurodegeneration with brain iron accumulation (NBIA). European Journal of Paediatric Neurology 2012, 16(2):175-178.
115. Litwin T., Gromadzka G., Szpak G.M., Jablonka-Salach K., Bulska E., Czlonkowska A. Brain metal accumulation in Wilson's disease. Journal of Neurological Sciences 2013, 329(1-2):55-58.
116. Liu C., Li W., Johnson G.A., Wu B. High-field (9.4T) MRI of brain dysmyelination by quantitative mapping of magnetic susceptibility. NeuroImage 2011, 56(3):930-938.
117. Liu J., Liu T., de Rochefort L., Ledoux J., Khalidov I., Chen W., et al. Morphology enabled dipole inversion for quantitative susceptibility mapping using structural consistency between the magnitude image and the susceptibility map. NeuroImage 2012, 59(3):2560-2568.
118. Liu T., Liu J., de Rochefort L., Spincemaille P., Khalidov I., Ledoux J.R., et al. Morphology enabled dipole inversion (MEDI) from a single-angle acquisition: Comparison with COSMOS in human brain imaging. Magnetic Resonance in Medicine 2011, 66(3):777-783.
119. Liu T., Spincemaille P., de Rochefort L., Kressler B., Wang Y. Calculation of susceptibility through multiple orientation sampling (COSMOS): A method for conditioning the inverse problem from measured magnetic field map to susceptibility source image in MRI. Magnetic Resonance in Medicine 2009, 61(1):196-204.
120. Lotfipour A.K., Wharton S., Schwarz S.T., Gontu V., Schafer A., Peters A.M., et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. Journal of Magnetic Resonance Imaging 2012, 35(1):48-55.
121. Luo J., He X., d'Avignon D.A., Ackerman J.J., Yablonskiy D.A. Protein-induced water 1H MR frequency shifts: Contributions from magnetic susceptibility and exchange effects. Journal of Magnetic Resonance 2010, 202(1):102-108.
122. Ma J., Wehrli F.W. Method for image-based measurement of the reversible and irreversible contribution to the transverse-relaxation rate. Journal of Magnetic Resonance. Series B 1996, 111(1):61-69.
123. Marques J.P., Maddage R., Mlynarik V., Gruetter R. On the origin of the MR image phase contrast: An in vivo MR microscopy study of the rat brain at 14.1T. NeuroImage 2009, 46(2):345-352.
124. McNeill A., Birchall D., Hayflick S.J., Gregory A., Schenk J.F., Zimmerman E.A., et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008, 70(18):1614-1619.
125. Meiboom S., Gill D. Modified spin-echo method for measuring nuclear relaxation times. Review of Scientific Instruments 1958, 29(8):688-691.
126. Michaeli S., Oz G., Sorce D.J., Garwood M., Ugurbil K., Majestic S., et al. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Movement Disorders 2007, 22(3):334-340.
127. Milton W.J., Atlas S.W., Lexa F.J., Mozley P.D., Gur R.E. Deep gray matter hypointensity patterns with aging in healthy adults: MR imaging at 1.5T. Radiology 1991, 181(3):715-719.
128. Nestrasil I., Michaeli S., Liimatainen T., Rydeen C.E., Kotz C.M., Nixon J.P., et al. T1rho and T2rho MRI in the evaluation of Parkinson's disease. Journal of Neurology 2010, 257(6):964-968.
129. Novellino F., Cherubini A., Chiriaco C., Morelli M., Salsone M., Arabia G., et al. Brain iron deposition in essential tremor: A quantitative 3-Tesla magnetic resonance imaging study. Movement Disorders 2013, 28(2):196-200.
130. Ogg R.J., Langston J.W., Haacke E.M., Steen R.G., Taylor J.S. The correlation between phase shifts in gradient-echo MR images and regional brain iron concentration. Magnetic Resonance Imaging 1999, 17(8):1141-1148.
131. Ogg R.J., Steen R.G. Age-related changes in brain T1 are correlated with iron concentration. Magnetic Resonance in Medicine 1998, 40(5):749-753.
132. Ordidge R.J., Gorell J.M., Deniau J.C., Knight R.A., Helpern J.A. Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magnetic Resonance in Medicine 1994, 32(3):335-341.
133. Peran P., Cherubini A., Assogna F., Piras F., Quattrocchi C., Peppe A., et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010, 133(11):3423-3433.
134. Peran P., Cherubini A., Luccichenti G., Hagberg G., Demonet J.F., Rascol O., et al. Volume and iron content in basal ganglia and thalamus. Human Brain Mapping 2009, 30(8):2667-2675.
135. Pfefferbaum A., Adalsteinsson E., Rohlfing T., Sullivan E.V. MRI estimates of brain iron concentration in normal aging: Comparison of field-dependent (FDRI) and phase (SWI) methods. NeuroImage 2009, 47(2):493-500.
136. Pott F., Gingele S., Clarner T., Dang J., Baumgartner W., Beyer C., et al. Cuprizone effect on myelination, astrogliosis and microglia attraction in the mouse basal ganglia. Brain Research 2009, 1305:137-149.
137. Pujol J., Junque C., Vendrell P., Grau J.M., Marti-Vilalta J.L., Olive C., et al. Biological significance of iron-related magnetic resonance imaging changes in the brain. Archives of Neurology 1992, 49(7):711-717.
138. Punwani S., Cooper C.E., Clemence M., Penrice J., Amess P., Thornton J., et al. Correlation between absolute deoxyhaemoglobin [dHb] measured by near infrared spectroscopy (NIRS) and absolute R2' as determined by magnetic resonance imaging (MRI). Advances in Experimental Medicine and Biology 1997, 413:129-137.
139. Rauscher A., Sedlacik J., Barth M., Mentzel H.J., Reichenbach J.R. Magnetic susceptibility-weighted MR phase imaging of the human brain. American Journal of Neuroradiology 2005, 26(4):736-742.
140. Reichenbach J.R. The future of susceptibility contrast for assessment of anatomy and function. NeuroImage 2012, 62(2):1311-1315.
141. Reichenbach J.R., Venkatesan R., Schillinger D.J., Kido D.K., Haacke E.M. Small vessels in the human brain: MR venography with deoxyhemoglobin as an intrinsic contrast agent. Radiology 1997, 204(1):272-277.
142. Reichenbach J.R., Venkatesan R., Yablonskiy D.A., Thompson M.R., Lai S., Haacke E.M. Theory and application of static field inhomogeneity effects in gradient-echo imaging. Journal of Magnetic Resonance Imaging 1997, 7(2):266-279.
143. Rhodes S.L., Ritz B. Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiology of Disease 2008, 32(2):183-195.
144. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. Journal of Neurochemistry 1989, 52(2):515-520.
145. Rohrer M., Bauer H., Mintorovitch J., Requardt M., Weinmann H.J. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Investigative Radiology 2005, 40(11):715-724.
146. Sastry S., Arendash G.W. Time-dependent changes in iron levels and associated neuronal loss within the substantia nigra following lesions within the neostriatum/globus pallidus complex. Neuroscience 1995, 67(3):649-666.
147. Sati P., Silva A.C., van Gelderen P., Gaitan M.I., Wohler J.E., Jacobson S., et al. In vivo quantification of T(2) anisotropy in white matter fibers in marmoset monkeys. NeuroImage 2012, 59(2):979-985.
148. Saudek F., Jirak D., Girman P., Herynek V., Dezortova M., Kriz J., et al. Magnetic resonance imaging of pancreatic islets transplanted into the liver in humans. Transplantation 2010, 90(12):1602-1606.
149. Schenck J.F. Health and physiological effects of human exposure to whole-body four-tesla magnetic fields during MRI. Annals of the New York Academy of Sciences 1992, 649:285-301.
150. Schenck J.F. The role of magnetic susceptibility in magnetic resonance imaging: MRI magnetic compatibility of the first and second kinds. Medical Physics 1996, 23(6):815-850.
151. Schenck J.F. Magnetic resonance imaging of brain iron. Journal of the Neurological Sciences 2003, 207(1-2):99-102.
152. Schenck J.F., Zimmerman E.A. High-field magnetic resonance imaging of brain iron: Birth of a biomarker?. NMR in Biomedicine 2004, 17(7):433-445.
153. Schenker C., Meier D., Wichmann W., Boesiger P., Valavanis A. Age distribution and iron dependency of the T2 relaxation time in the globus pallidus and putamen. Neuroradiology 1993, 35(2):119-124.
154. Schipper H.M. Neurodegeneration with brain iron accumulation-Clinical syndromes and neuroimaging. Biochimica et Biophysica Acta 2012, 1822(3):350-360.
155. Schneider S.A., Dusek P., Hardy J., Westenberger A., Jankovic J., Bhatia K.P. Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA). Current Neuropharmacology 2013, 11(1):59-79.
156. Schrag M., McAuley G., Pomakian J., Jiffry A., Tung S., Mueller C., et al. Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: A postmortem MRI study. Acta Neuropathologica 2010, 119(3):291-302.
157. Schroder N., Figueiredo L.S., de Lima M.N. Role of brain iron accumulation in cognitive dysfunction: Evidence from animal models and human studies. Journal of Alzheimer's Disease 2013, 34(4):797-812.
158. Schweser F., Deistung A., Lehr B.W., Reichenbach J.R. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Medical Physics 2010, 37(10):5165-5178.
159. Schweser F., Deistung A., Lehr B.W., Reichenbach J.R. Quantitative imaging of intrinsic magnetic tissue properties using MRI signal phase: An approach to in vivo brain iron metabolism?. NeuroImage 2011, 54(4):2789-2807.
160. Schweser F., Deistung A., Sommer K., Reichenbach J.R. Toward online reconstruction of quantitative susceptibility maps: Superfast dipole inversion. Magnetic Resonance in Medicine 2013, 69(6):1581-1593.
161. Shmueli K., de Zwart J.A., van Gelderen P., Li T.Q., Dodd S.J., Duyn J.H. Magnetic susceptibility mapping of brain tissue in vivo using MRI phase data. Magnetic Resonance in Medicine 2009, 62(6):1510-1522.
162. Shmueli K., Dodd S.J., Li T.Q., Duyn J.H. The contribution of chemical exchange to MRI frequency shifts in brain tissue. Magnetic Resonance in Medicine 2011, 65(1):35-43.
163. Sian-Hulsmann J., Mandel S., Youdim M.B., Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Journal of Neurochemistry 2011, 118(6):939-957.
164. Stankiewicz J., Panter S.S., Neema M., Arora A., Batt C.E., Bakshi R. Iron in chronic brain disorders: Imaging and neurotherapeutic implications. Neurotherapeutics 2007, 4(3):371-386.
165. Stark D.D., Bass N.M., Moss A.A., Bacon B.R., McKerrow J.H., Cann C.E., et al. Nuclear magnetic resonance imaging of experimentally induced liver disease. Radiology 1983, 148(3):743-751.
166. Sulzer D., Mosharov E., Talloczy Z., Zucca F.A., Simon J.D., Zecca L. Neuronal pigmented autophagic vacuoles: Lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease. Journal of Neurochemistry 2008, 106(1):24-36.
167. Supprian T., Hofmann E., Warmuth-Metz M., Franzek E., Becker T. MRI T2 relaxation times of brain regions in schizophrenic patients and control subjects. Psychiatry Research 1997, 75(3):173-182.
168. Tanaka A., Ueno Y., Nakayama Y., Takano K., Takebayashi S. Small chronic hemorrhages and ischemic lesions in association with spontaneous intracerebral hematomas. Stroke 1999, 30(8):1637-1642.
169. Tatsumi S., Shinohara M., Yamamoto T. Direct comparison of histology of microbleeds with postmortem MR images: A case report. Cerebrovascular Diseases 2008, 26(2):142-146.
170. Taylor E.M., Morgan E.H. Role of transferrin in iron uptake by the brain: A comparative study. Journal of Comparative Physiology. B 1991, 161(5):521-524.
171. Tennison M.B., Bouldin T.W., Whaley R.A. Mineralization of the basal ganglia detected by CT in Hallervorden-Spatz syndrome. Neurology 1988, 38(1):154-155.
172. Terman A., Kurz T. Lysosomal iron, iron chelation, and cell death. Antioxidants & Redox Signaling 2013, 18(8):888-898.
173. Todorich B., Pasquini J.M., Garcia C.I., Paez P.M., Connor J.R. Oligodendrocytes and myelination: The role of iron. Glia 2009, 57(5):467-478.
174. Tribl F., Marcus K., Meyer H.E., Bringmann G., Gerlach M., Riederer P. Subcellular proteomics reveals neuromelanin granules to be a lysosome-related organelle. Journal of Neural Transmission 2006, 113(6):741-749.
175. Van Kirk M.P., Larsen P.D., O'Connor P.S. New computed tomography scan finding in Hallervorden-Spatz syndrome. Journal of Clinical Neuro-Ophthalmology 1986, 6(2):86-90.
176. Vymazal J., Babis M., Brooks R.A., Filip K., Dezortova M., Hrncarkova H., et al. T1 and T2 alterations in the brains of patients with hepatic cirrhosis. American Journal of Neuroradiology 1996, 17(2):333-336.
177. Vymazal J., Brooks R.A., Baumgarner C., Tran V., Katz D., Bulte J.W., et al. The relation between brain iron and NMR relaxation times: An in vitro study. Magnetic Resonance in Medicine 1996, 35(1):56-61.
178. Vymazal J., Brooks R.A., Zak O., McRill C., Shen C., Di Chiro G. T1 and T2 of ferritin at different field strengths: Effect on MRI. Magnetic Resonance in Medicine 1992, 27(2):368-374.
179. Vymazal J., Bulte J.W., Frank J.A., Di Chiro G., Brooks R.A. Frequency dependence of MR relaxation times I. Paramagnetic ions. Journal of Magnetic Resonance Imaging 1993, 3(4):637-640.
180. Vymazal J., Hajek M., Patronas N., Giedd J.N., Bulte J.W., Baumgarner C., et al. The quantitative relation between T1-weighted and T2-weighted MRI of normal gray matter and iron concentration. Journal of Magnetic Resonance Imaging 1995, 5(5):554-560.
181. Vymazal J., Klempir J., Jech R., Zidovska J., Syka M., Ruzicka E., et al. MR relaxometry in Huntington's disease: Correlation between imaging, genetic and clinical parameters. Journal of Neurological Sciences 2007, 263(1-2):20-25.
182. Vymazal J., Righini A., Brooks R.A., Canesi M., Mariani C., Leonardi M., et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: Relation to iron content. Radiology 1999, 211(2):489-495.
183. Vymazal J., Zak O., Bulte J.W., Aisen P., Brooks R.A. T1 and T2 of ferritin solutions: Effect of loading factor. Magnetic Resonance in Medicine 1996, 36(1):61-65.
184. Wallis L.I., Paley M.N., Graham J.M., Grunewald R.A., Wignall E.L., Joy H.M., et al. MRI assessment of basal ganglia iron deposition in Parkinson's disease. Journal of Magnetic Resonance Imaging 2008, 28(5):1061-1067.
185. Walsh A.J., Lebel R.M., Eissa A., Blevins G., Catz I., Lu J.Q., et al. Multiple sclerosis: Validation of MR imaging for quantification and detection of iron. Radiology 2013, 267(2):531-542.
186. Wang Y., Butros S.R., Shuai X., Dai Y., Chen C., Liu M., et al. Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. American Journal of Neuroradiology 2012, 33(2):266-273.
187. Wang D., Li W.B., Wei X.E., Li Y.H., Dai Y.M. An investigation of age-related iron deposition using susceptibility weighted imaging. PLoS One 2012, 7(11):e50706.
188. Wang Y., Yu Y., Li D., Bae K.T., Brown J.J., Lin W., et al. Artery and vein separation using susceptibility-dependent phase in contrast-enhanced MRA. Journal of Magnetic Resonance Imaging 2000, 12(5):661-670.
189. Wang D., Zhu D., Wei X.E., Li Y.H., Li W.B. Using susceptibility-weighted images to quantify iron deposition differences in amnestic mild cognitive impairment and Alzheimer's disease. Neurology India 2013, 61(1):26-34.
190. Wharton S., Bowtell R. Whole-brain susceptibility mapping at high field: A comparison of multiple- and single-orientation methods. NeuroImage 2010, 53(2):515-525.
191. Wharton S., Schafer A., Bowtell R. Susceptibility mapping in the human brain using threshold-based k-space division. Magnetic Resonance in Medicine 2010, 63(5):1292-1304.
192. Wheaton A.J., Borthakur A., Corbo M.T., Moonis G., Melhem E., Reddy R. T2rho-weighted contrast in MR images of the human brain. Magnetic Resonance in Medicine 2004, 52(6):1223-1227.
193. Whittall K.P., MacKay A.L., Graeb D.A., Nugent R.A., Li D.K., Paty D.W. In vivo measurement of T2 distributions and water contents in normal human brain. Magnetic Resonance in Medicine 1997, 37(1):34-43.
194. Wisnieff C., Liu T., Spincemaille P., Wang S., Zhou D., Wang Y. Magnetic susceptibility anisotropy: Cylindrical symmetry from macroscopically ordered anisotropic molecules and accuracy of MRI measurements using few orientations. NeuroImage 2013, 70:363-376.
195. Wood J.C., Fassler J.D., Meade T. Mimicking liver iron overload using liposomal ferritin preparations. Magnetic Resonance in Medicine 2004, 51(3):607-611.
196. Xu X., Wang Q., Zhang M. Age, gender, and hemispheric differences in iron deposition in the human brain: An in vivo MRI study. NeuroImage 2008, 40(1):35-42.
197. Yamada N., Imakita S., Sakuma T., Takamiya M. Intracranial calcification on gradient-echo phase image: Depiction of diamagnetic susceptibility. Radiology 1996, 198(1):171-178.
198. Yan S., Sun J., Chen Y., Selim M., Lou M. Brain iron deposition in white matter hyperintensities: A 3-T MRI study. Age (Dordr) 2013, 35(5):1927-1936.
199. Yan S.Q., Sun J.Z., Yan Y.Q., Wang H., Lou M. Evaluation of brain iron content based on magnetic resonance imaging (MRI): Comparison among phase value, R2 and magnitude signal intensity. PLoS One 2012, 7(2):e31748.
200. Yao B., Bagnato F., Matsuura E., Merkle H., van Gelderen P., Cantor F.K., et al. Chronic multiple sclerosis lesions: Characterization with high-field-strength MR imaging. Radiology 2012, 262(1):206-215.
201. Yao B., Li T.Q., Gelderen P., Shmueli K., de Zwart J.A., Duyn J.H. Susceptibility contrast in high field MRI of human brain as a function of tissue iron content. NeuroImage 2009, 44(4):1259-1266.
202. Young I.R., Cox I.J., Bryant D.J., Bydder G.M. The benefits of increasing spatial resolution as a means of reducing artifacts due to field inhomogeneities. Magnetic Resonance Imaging 1988, 6(5):585-590.
203. Zecca L., Berg D., Arzberger T., Ruprecht P., Rausch W.D., Musicco M., et al. In vivo detection of iron and neuromelanin by transcranial sonography: A new approach for early detection of substantia nigra damage. Movement Disorders 2005, 20(10):1278-1285.
204. Zecca L., Gallorini M., Schunemann V., Trautwein A.X., Gerlach M., Riederer P., et al. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: Consequences for iron storage and neurodegenerative processes. Journal of Neurochemistry 2001, 76(6):1766-1773.
205. Zhang N., Fitsanakis V.A., Erikson K.M., Aschner M., Avison M.J., Gore J.C. A model for the analysis of competitive relaxation effects of manganese and iron in vivo. NMR in Biomedicine 2009, 22(4):391-404.
206. Zheng W., Nichol H., Liu S., Cheng Y.C., Haacke E.M. Measuring iron in the brain using quantitative susceptibility mapping and X-ray fluorescence imaging. NeuroImage 2013, 78:68-74.
207. Zhong K., Ernst T., Buchthal S., Speck O., Anderson L., Chang L. Phase contrast imaging in neonates. NeuroImage 2011, 55(3):1068-1072.
208. Zhong K., Leupold J., von Elverfeldt D., Speck O. The molecular basis for gray and white matter contrast in phase imaging. NeuroImage 2008, 40(4):1561-1566.
209. Zorzi G., Zibordi F., Chiapparini L., Bertini E., Russo L., Piga A., et al. Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial. Movement Disorders 2011, 26(9):1756-1759.